The oncogenic activation of RET in MTC occurs predominantly by mutations within RET that constitutively activate RET kinase, resulting in constitutive activation of downstream molecules such as MEK and ERK as well as PI3K/AKT/mTOR (PI3K) signaling pathways. This evidence concerns the gene RET and medullary thyroid gland carcinoma.